17 results about "Clotrimazole" patented technology

This invention provides an siRNA nucleic acid pesticide targeting the DICER2 gene to control rice blast fungus, belonging to the field of biotechnology. The siRNA molecule can delay and inhibit the formation of rice blast fungus appressoria, thereby reducing the pathogenicity of the fungus and providing a new method for controlling rice blast. When used in combination with tricyclazole or clotrimazole, it has a synergistic effect. The siRNA molecule targeting the DICER2 gene is prepared into a nucleic acid pesticide and sprayed on rice leaves, effectively reducing rice blast lesions and their area, thus enabling its use in rice blast control. Furthermore, it avoids the cumbersome process of cultivating genetically modified crops and addresses consumer concerns.

The invention belongs to the technical field of medicine, and particularly provides application of clotrimazole in preparation of a medicine for preventing and relieving cisplatin toxicity, the clotrimazole is an artificially synthesized imidazole antifungal compound, and the purity of the clotrimazole is 99.97% or above; the protective effect of clotrimazole in hair cells and hair cell lines of cochlea basilar membranes cultured in vitro is verified through HEI-OC1 cell culture and C57 mouse basilar membrane culture, and the in-vivo effect of clotrimazole is verified through tympanic injection of C57 mice; besides, the research test of clotrimazole for mouse cis-platinum ear toxicity shows that hearing thresholds of all frequencies after cis-platinum treatment are obviously increased, ABR threshold offset caused by cis-platinum is reduced by injection of clotrimazole into tympanic chambers, hair cell loss of all gynaecology is greatly improved due to the protection effect of clotrimazole, and the cis-platinum ear toxicity of mice is improved. Finally, the clotrimazole is proved to have a remarkable effect on prevention or treatment of cisplatin toxicity.

The application belongs to the technical field of medical intermediates, and relates to a production method of a clotrimazole intermediate (2-chlorophenyl)diphenylmethanol. In the method, 2-methyltetrahydrofuran or cyclopentyl methyl ether is used as a reaction solvent, an ethyl o-chlorobenzoate solution is added dropwise into a phenyl magnesium bromide solution with a concentration of 2.5-3.5 M under the conditions of 60-80 DEG C and inert atmosphere, the reaction is continuously carried out after the dropwise addition is completed, a water solution of a quenching agent is added after the reaction to quench, then, liquid separation is carried out, and the organic phase after the liquid separation is concentrated to obtain a crude product; the crude product is refined by using a reaction solvent and petroleum ether, and (2-chlorophenyl)diphenylmethanol is obtained. The production method can efficiently and stably produce high-quality (2-chlorophenyl)diphenylmethanol, reduces production cost and safety hazards, and can be used for large-scale industrial production.

1. The name of the design product: medicine packaging box (clotrimazole cream). 2. The use of the design product: used for packaging and storing medicines and medical products. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention relates to otological formulations, methods and devices. The present invention relates to a formulation and a method for treating ear infections, in particular auricular mycosis and otitis externa, by single administration. The formulations comprise an antibiotic, an antifungal agent and an anti-inflammatory agent added to a thick ear carrier. In one embodiment, the formulation comprises a therapeutically effective amount of an active ingredient, including marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

Described herein are topical compositions containing one or more of an antibacterial, an antifungal, and an anti-inflammatory, for use in supporting the health of a subject, including preventing or treating a fungal infection, a yeast infection, a bacterial infection, inflammation, or any combination thereof. A preferred formulation comprises mupirocin calcium in an amount of about 0.5% v / v, terbinafine hydrochloride in an amount of about 0.25% v / v, clotrimazole in an amount of about 0.25% v / v, and hydrocortisone acetate in an amount of about 0.25% v / v.

The invention relates to a compound medicine for treating vulva lichen sclerosus. The compound medicine is prepared from methylrosanilinium chloride, aminoglycoside antibiotics, glucocorticoid, pyrrole broad-spectrum antifungal drugs and pharmaceutic adjuvants. The aminoglycoside antibiotic is tobramycin, the glucocorticoid is dexamethasone, and the pyrrole broad-spectrum antifungal drug is clotrimazole. The compound medicine is ointment or water aqua.

A method of using a pharmaceutical composition comprising metronidazole, clotrimazole and chlorhexidine for treating patients suffering from hemorrhoids, is disclosed. The mixture of metronidazole, clotrimazole and chlorhexidine can be applied to contact the hemorrhoids to relieve and / or reduce the symptoms caused by the hemorrhoids. Various application forms including solid forms and solution forms of the mixture of compounds can be used to treat the hemorrhoids.

The invention belongs to the technical field of hand and foot nursing, and discloses a non-corrosive body surface cutin hyperplasia nursing patch as well as a preparation method and application thereof. The nursing patch is sequentially provided with a three-layer basic structure including a bacteriostatic functional layer, a flexible substrate and a breathable protective layer from the skin contact side to the outer side, the bacteriostatic functional layer is compounded by clotrimazole, bifonazole and ketoconazole, and the mass ratio of clotrimazole to bifonazole to ketoconazole is (1-2): (1.5-2.5): (0.6-1.5). According to the non-corrosive body surface cutin hyperplasia nursing patch, the root of cutin abnormal hyperplasia is cut off through the antibacterial components, meanwhile, cutin is mildly softened and ablated, and normal skin barriers are not damaged.

Therapeutic compositions, kits, and methods and uses thereof are provided. The compositions comprise zinc oxide, hydrocortisone, and / or clotrimazole.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The present application relates to a kind of lactobacillus johnsonii and application, belong to microbial technology field.Lactobacillus johnsonii JoA9-1 of the present application is preserved in China typical culture preservation center, and the preservation number is CCTCCM2025369.Lactobacillus johnsonii JoA9-1 of the present application has no virulence factor, does not hemolyze, and has good safety, and its beneficial effect is: can produce multiple organic acids and has tolerance to acidic environment, can adapt and maintain the acidic environment of female genital tract;Can inhibit the propagation of pathogenic bacteria;Can inhibit the formation of Candida albicans hypha;It has immune regulation function, and the inhibitory effect on inflammatory factor TNF alpha is superior to clotrimazole treatment, can significantly enhance mouse vaginitis treatment;Treatment occurs in the site of vagina infection, can repair the local tissue of Candida albicans vaginitis mouse;Regulate the relative abundance of vaginal microbial flora after Candida albicans vaginitis infection of mouse, restore vaginal microbial flora environment.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

The invention relates to the field of veterinary drugs, in particular to a pharmaceutical composition for preventing and treating rabbit dermatomycosis as well as a preparation method and application thereof. The pharmaceutical composition is prepared from the following raw materials in percentage by weight: 0.5%-2% of clotrimazole, 1%-5% of 5% gentamicin sulfate powder, 20%-40% of sulfur powder, 50%-75% of talcum powder, 2%-6% of 32.5% neomycin sulfate powder and the balance of water. According to the composition, clotrimazole is introduced as a core antifungal component, a targeting action mechanism of specific inhibition of fungal cytochrome P-450 of clotrimazole is utilized, and a non-specific bactericidal effect of sulfur powder is combined, so that synergistic interaction is realized.

The invention belongs to the field of biological medicines, and particularly discloses an FN-coated drug-loaded chitosan nanogel system as well as a preparation method and application thereof. According to the system, chitosan nanogel (CS NGs) is taken as a carrier, an antifungal drug clotrimazole (CLO) is loaded, and fibronectin (FN) is coated on the surface of the chitosan nanogel through electrostatic adsorption. The nanogel system has a pH-responsive drug release characteristic, and the release rate in an acidic environment (pH 5.5) is significantly higher than that in a neutral environment (pH 7.4). The preparation method comprises the following steps: preparing the CS NGs by a micro-emulsion method, loading the medicine and coating the FN. The system can significantly improve the water solubility and membrane permeability of clotrimazole, prolong the vagina retention time and promote the proliferation and migration of epithelial cells, and has anti-inflammatory and tissue repair functions. Experiments show that the system has a remarkable treatment effect on vulvovaginal candidiasis (VVC) and can be used for preparing drugs for treating VVC.

The invention discloses anti-aging, moisturizing and antibacterial vaginal gel, and belongs to the field of daily necessities for health. The gel is composed of a solution A, a solution B and a solution C, wherein the solution A contains 15-25 parts of glycerol, 10-15 parts of sodium hyaluronate and 1-5 parts of xanthan gum; the solution B is prepared from 0.5 to 2 parts of hydroxyethyl cellulose and 1 to 2 parts of carboxymethyl chitosan; the solution C contains 0.5-3 parts of beta-nicotinamide mononucleotide, 0.5-1.5 parts of an antibacterial agent and 0.1-0.8 part of a transdermal absorption enhancer, and further contains coenzyme Q10 and a centella asiatica extract or a lactobacillus fermentation product on the basis. The antibacterial rate of the vaginal gel to pathogenic bacteria is greater than or equal to 99.5%, lactobacilli are not interfered, vaginal epithelial cell collagen can be improved by 35% or above, the mitochondrial activity can be improved by 40%, and the vaginal gel is suitable for preventing infection, delaying tissue aging and maintaining micro-ecological balance and can also be combined with clotrimazole to enhance the antifungal curative effect.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.